EASL2020：最新肝病领域「重磅研究」概览！

2020年8月27～29日，第55届欧洲肝脏研究学会年会（EASL2020）暨国际肝脏会议（TheDigitalInternationalLiverCongress™2020，ILC2020）将在欧洲最大的城市——英国·伦敦盛大召开。

既往欧洲国际肝病大会现场都会汇集来自世界各地的专家，借此了解肝脏研究的最新进展。与以往不同的是，鉴于COVID-19大流行的影响，今年大会完全改为线上举行。

今年大会共收集了来自55个国家专家学者的研究摘要，其中1470+多篇原创研究成果将在壁报和视频展示。依照惯例，今年筛选出8项最新突破研究和13项重磅研究分别在最新突破专题（LateBreaker）和全体大会（Generalsession）由团队代表进行口头报告。重磅研究见下：

GS01苯扎贝特（Bezafibrate）联合治疗可提高原发性胆管炎无肝移植患者的存活率：一项日本全国性队列研究

GS01Bezafibrateadd-ontherapyimproveslivertransplantation-freesurvivalinpatientswithprimarybiliarycholangitis:aJapanesenationwidecohortstudy

AtsushiTanaka,JapanCo-author:ChristopheCorpechot

27August202013:15-13:30

GS02粪便亚基因组中的毒性相关基因与酒精性肝炎患者死亡率相关

GS02Virulence-relatedgenesinfaecalmetagenomesassociatedwithmortalityinpatientswithalcoholichepatitis

SonjaLang,UnitedStatesCo-author:BerndSchnabl

27August202013:30-13:45

GS03端粒相关基因突变患者的肝脏受累：患病率、临床、影像学、病理学特征、转归和危险因素

GS03Liverinvolvementinpatientswithtelomere-relatedgenesmutations:prevalence,clinical,radiological,pathologicalfeatures,outcomeandriskfactors

SabrinaSIDALI,FranceCo-author:AuréliePlessier

27August202013:45-14:00

GS04肠道微生物群通过促进TLR4依赖的单核细胞髓源性抑制细胞的增殖来促进肝癌发生

GS04GutmicrobiotadriveshepatocarcinogenesisbypromotingTLR4-dependentexpansionofmonocyticmyeloid-derivedsuppressorcells

KaiMarkusSchneider,GermanyCo-author:AntjeMohs

27August202014:00-14:15

GS05欧洲国家器官储运组织终末期肝病钠评分的模型验证

GS05ValidationoftheModelforEnd-stageLiverDiseasesodiumscorefortheEurotransplantregion.

BenGoudsmit,NetherlandsCo-author:BartVanHoek

27August202014:15-14:30

GS06一项随机、多中心、双盲、安慰剂对照试验：左旋肉碱对肝硬化患者和隐性肝性脑病患者生活质量的影响

GS06Arandomised,multi-centre,double-blinded,placebocontrolled,investigator-initiatedtrialtoassesstheimpactofL-carnitineadministrationonqualityoflifeincirrhosispatientsandcoverthepaticencephalopathy

EileenYoon,Korea,Rep.ofSouth

27August202014:30-14:45

GS07Nidufexor，一种非胆汁酸FXR激动剂，在给药12周后降低NASH患者的ALT水平和肝脂肪分数

GS07Nidufexor,anon-bileacidFXRagonist,decreasesALTandhepaticfatfractioninpatientswithNASHafter12weeksdosing

RichardAspinall,UnitedKingdomCo-author:MichaelBadman

27August202014:45-15:00

GS08在初级保健中引入"reflex"AST检测可提高晚期肝病的检出率：TheGwentASTProject（GAP）

GS08Introductionof"reflex"ASTtestinginprimarycareincreasesdetectionofadvancedliverdisease:TheGwentASTProject(GAP)

AndrewYeoman,UnitedKingdomCo-author:Dr.FidanYousuf

28August202013:30-13:45

GS09单酰甘油脂肪酶重组巨噬细胞和肝细胞的脂质代谢，促进肝再生

GS09Monoacylglycerollipasereprogrammeslipidmetabolisminmacrophagesandhepatocytestopromoteliverregeneration

ManonAllaire,FranceCo-author:HélèneGilgenkrantz

28August202013:45-14:00

GS10在接受核苷类似物治疗的慢性乙型肝炎患者中，用RNA干扰疗法（JNJ-3989）进行短期治疗可持续抑制乙型肝炎表面抗原

GS10Short-termtreatmentwithRNAinterferencetherapy,JNJ-3989,resultsinsustainedhepatitisBsurfaceantigensuppressioninpatientswithchronichepatitisBreceivingnucleos(t)ideanaloguetreatment

EdwardGane,NewZealandCo-author:StephenLocarnini

28August202014:00-14:15

GS11巨噬细胞清道夫受体1介导肥胖相关非酒精性脂肪肝的脂质性炎症反应

GS11MacrophageScavengerReceptor1mediateslipid-inducedinflammationinhumanobesity-relatednon-alcoholicfattyliverdisease

OlivierGovaere,UnitedKingdomCo-author:QuentinAnstee

28August202014:15-14:30

GS12自身免疫性肝炎肝移植术后患者和移植物的长期存活率

GS12Long-termpatientandgraftsurvivalafterlivertransplantationforautoimmunehepatitis

MelinaHeinemann,GermanyCo-author:ChristophSchramm

28August202014:30-14:45

GS13HCV消除后肝硬化患者血清常规参数和AFP演变的分析，用于HCC风险分层：来自ANRSCO12CirVir队列的轨迹聚群分析

GS13ProfilingofRoutineserumparametersandAFPevolutionincirrhosisfollowingHCVeradicationforstratificationofHCCrisk:atrajectoryclusteringanalysisfromtheANRSCO12CirVircohort

PierreNahon,FranceCo-author:EtienneAudureau

28August202014:45-15:00

信源：ESAL官网